中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(4): 961-964

Research advances in microRNA-200c in pancreatic cancer

DOI: 10.3969/j.issn.1001-5256.2022.04.045

  • Department of Hepatopancreatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China

Research funding:

Science and Technology Key Project of Henan Province (162102310315)

More Information
  • Corresponding author: MA Chao, mjc1566@sina.com(ORCID: 0000-0002-6894-1259)
  • Received Date: 2021-07-31
  • Accepted Date: 2021-10-26
  • Published Date: 2022-04-20
    Abstract
  • MicroRNA-200c (miR-200c) is a type of non-coding small molecule RNA, which is involved in the post-transcriptional regulation of genes and is closely associated with the development and progression of tumor. This article introduces the inhibitory effect of miR-200c on the invasion and metastasis of pancreatic cancer and the clinical application value of miR-200c in the early diagnosis and prognostic evaluation of pancreatic cancer. It is pointed out that miR-200c can be used as a tumor suppressor gene and an effective molecular marker for further clinical research.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    VINCENT A, HERMAN J, SCHULICK R, et al. Pancreatic cancer[J]. Lancet, 2011, 378(9791): 607-620. DOI: 10.1016/S0140-6736(10)62307-0.
    [2]
    RACHAGANI S, MACHA MA, HEIMANN N, et al. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer[J]. Adv Drug Deliv Rev, 2015, 81: 16-33. DOI: 10.1016/j.addr.2014.10.020.
    [3]
    CHAN B, MANLEY J, LEE J, et al. The emerging roles of microRNAs in cancer metabolism[J]. Cancer Lett, 2015, 356(2 Pt A): 301-308. DOI: 10.1016/j.canlet.2014.10.011.
    [4]
    BERINDAN-NEAGOE I, MONROIG PDEL C, PASCULLI B, et al. MicroRNAome genome: A treasure for cancer diagnosis and therapy[J]. CA Cancer J Clin, 2014, 64(5): 311-336. DOI: 10.3322/caac.21244.
    [5]
    FENG X, WANG Z, FILLMORE R, et al. MiR-200, a new star miRNA in human cancer[J]. Cancer Lett, 2014, 344(2): 166-173. DOI: 10.1016/j.canlet.2013.11.004.
    [6]
    LIU PF, JIANG WH, HAN YT, et al. Integrated microRNA-mRNA analysis of pancreatic ductal adenocarcinoma[J]. Genet Mol Res, 2015, 14(3): 10288-10297. DOI: 10.4238/2015.August.28.14.
    [7]
    KARAMITOPOULOU E, HAEMMIG S, BAUMGARTNER U, et al. MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer[J]. Mod Pathol, 2017, 30(8): 1116-1125. DOI: 10.1038/modpathol.2017.35.
    [8]
    KUMAR S, NAG A, MANDAL CC. A comprehensive review on miR-200c, a promising cancer biomarker with therapeutic potential[J]. Curr Drug Targets, 2015, 16(12): 1381-1403. DOI: 10.2174/1389450116666150325231419.
    [9]
    BYUN Y, CHOI YC, JEONG Y, et al. MiR-200c downregulates HIF-1α and inhibits migration of lung cancer cells[J]. Cell Mol Biol Lett, 2019, 24: 28. DOI: 10.1186/s11658-019-0152-2.
    [10]
    VESCARELLI E, GERINI G, MEGIORNI F, et al. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1[J]. J Exp Clin Cancer Res, 2020, 39(1): 3. DOI: 10.1186/s13046-019-1490-7.
    [11]
    ALI S, SALEH H, SETHI S, et al. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer[J]. Br J Cancer, 2012, 107(8): 1354-1360. DOI: 10.1038/bjc.2012.383.
    [12]
    PAN Y, LU F, XIONG P, et al. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC[J]. J Exp Clin Cancer Res, 2018, 37(1): 167. DOI: 10.1186/s13046-018-0848-6.
    [13]
    PERUSINA LANFRANCA M, THOMPSON JK, BEDNAR F, et al. Metabolism and epigenetics of pancreatic cancer stem cells[J]. Semin Cancer Biol, 2019, 57: 19-26. DOI: 10.1016/j.semcancer.2018.09.008.
    [14]
    MA C, HUANG T, DING YC, et al. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells[J]. Int J Clin Exp Pathol, 2015, 8(6): 6533-6539.
    [15]
    GABLO N, TRACHTOVA K, PROCHAZKA V, et al. Identification and validation of circulating micrornas as prognostic biomarkers in pancreatic ductal adenocarcinoma patients undergoing surgical resection[J]. J Clin Med, 2020, 9(8): 2440. DOI: 10.3390/jcm9082440.
    [16]
    THIERY JP, SLEEMAN JP. Complex networks orchestrate epithelial-mesenchymal transitions[J]. Nat Rev Mol Cell Biol, 2006, 7(2): 131-142. DOI: 10.1038/nrm1835.
    [17]
    AIELLO NM, KANG Y. Context-dependent EMT programs in cancer metastasis[J]. J Exp Med, 2019, 216(5): 1016-1026. DOI: 10.1084/jem.20181827.
    [18]
    ZHOU P, LI B, LIU F, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: Implication for treatment resistance in pancreatic cancer[J]. Mol Cancer, 2017, 16(1): 52. DOI: 10.1186/s12943-017-0624-9.
    [19]
    PASTUSHENKO I, BLANPAIN C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. DOI: 10.1016/j.tcb.2018.12.001.
    [20]
    BAKIR B, CHIARELLA AM, PITARRESI JR, et al. EMT, MET, plasticity, and tumor metastasis[J]. Trends Cell Biol, 2020, 30(10): 764-776. DOI: 10.1016/j.tcb.2020.07.003.
    [21]
    DYKXHOORN DM. MicroRNAs and metastasis: Little RNAs go a long way[J]. Cancer Res, 2010, 70(16): 6401-6406. DOI: 10.1158/0008-5472.CAN-10-1346.
    [22]
    GREGORY PA, BERT AG, PATERSON EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1[J]. Nat Cell Biol, 2008, 10(5): 593-601. DOI: 10.1038/ncb1722.
    [23]
    BURK U, SCHUBERT J, WELLNER U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells[J]. EMBO Rep, 2008, 9(6): 582-589. DOI: 10.1038/embor.2008.74.
    [24]
    DIAZ-RIASCOS ZV, GINESTA MM, FABREGAT J, et al. Expression and role of MicroRNAs from the miR-200 family in the tumor formation and metastatic propensity of pancreatic cancer[J]. Mol Ther Nucleic Acids, 2019, 17: 491-503. DOI: 10.1016/j.omtn.2019.06.015.
    [25]
    KATOCH A, JAMWAL VL, FAHEEM MM, et al. Overlapping targets exist between the Par-4 and miR-200c axis which regulate EMT and proliferation of pancreatic cancer cells[J]. Transl Oncol, 2021, 14(1): 100879. DOI: 10.1016/j.tranon.2020.100879.
    [26]
    BRACKEN CP, GREGORY PA, KOLESNIKOFF N, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition[J]. Cancer Res, 2008, 68(19): 7846-7854. DOI: 10.1158/0008-5472.CAN-08-1942.
    [27]
    WELLNER U, SCHUBERT J, BURK UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs[J]. Nat Cell Biol, 2009, 11(12): 1487-1495. DOI: 10.1038/ncb1998.
    [28]
    MA C, DING YC, YU W, et al. MicroRNA-200c overexpression plays an inhibitory role in human pancreatic cancer stem cells by regulating epithelial-mesenchymal transition[J]. Minerva Med, 2015, 106(4): 193-202.
    [29]
    RADHAKRISHNAN P, MOHR AM, GRANDGENETT PM, et al. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer[J]. PLoS One, 2013, 8(10): e73356. DOI: 10.1371/journal.pone.0073356.
    [30]
    HUANG CC, LIN CM, HUANG YJ, et al. Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells[J]. Biotechnol Appl Biochem, 2017, 64(2): 165-173. DOI: 10.1002/bab.1446.
    [31]
    STOICA AF, CHANG CH, PAUKLIN S. Molecular therapeutics of pancreatic ductal adenocarcinoma: Targeted pathways and the role of cancer stem cells[J]. Trends Pharmacol Sci, 2020, 41(12): 977-993. DOI: 10.1016/j.tips.2020.09.008.
    [32]
    RAGUSA M, BARBAGALLO C, BREX D, et al. Molecular crosstalking among noncoding RNAs: A new network layer of genome regulation in cancer[J]. Int J Genomics, 2017, 2017: 4723193. DOI: 10.1155/2017/4723193.
    [33]
    ZHUO M, YUAN C, HAN T, et al. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis[J]. BMC Cancer, 2018, 18(1): 1032. DOI: 10.1186/s12885-018-4954-9.
    [34]
    SOUBANI O, ALI AS, LOGNA F, et al. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer[J]. Carcinogenesis, 2012, 33(8): 1563-1571. DOI: 10.1093/carcin/bgs189.
    [35]
    HUANG GL, SUN J, LU Y, et al. MiR-200 family and cancer: From a meta-analysis view[J]. Mol Aspects Med, 2019, 70: 57-71. DOI: 10.1016/j.mam.2019.09.005.
    [36]
    LI Y, VANDENBOOM TG 2nd, KONG D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells[J]. Cancer Res, 2009, 69(16): 6704-6712. DOI: 10.1158/0008-5472.CAN-09-1298.
    [37]
    ARUMUGAM T, RAMACHANDRAN V, FOURNIER KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer[J]. Cancer Res, 2009, 69(14): 5820-5828. DOI: 10.1158/0008-5472.CAN-08-2819.
    [38]
    CHITKARA D, MITTAL A, MAHATO RI. miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies[J]. Adv Drug Deliv Rev, 2015, 81: 34-52. DOI: 10.1016/j.addr.2014.09.006.
    [39]
    WANG ZG, YANG R, PENG MJ, et al. Research advances of exosome miRNA-mediated drug-resistance in pancreatic cancer[J]. Chin J Dig Surg, 2021, 20(4): 471-478. DOI: 10.3760/cma.j.cn115610-20210219-00081.

    王智刚, 杨睿, 彭敏劼, 等. 外泌体微小RNAs介导的胰腺癌耐药机制研究进展[J]. 中华消化外科杂志, 2021, 20(4): 471-478. DOI: 10.3760/cma.j.cn115610-20210219-00081.
    [40]
    TAKEI Y, KADOMATSU K, YUZAWA Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics[J]. Cancer Res, 2004, 64(10): 3365-3370. DOI: 10.1158/0008-5472.CAN-03-2682.
    [41]
    MEKALA JR, NAUSHAD SM, PONNUSAMY L, et al. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer[J]. Gene, 2018, 641: 248-258. DOI: 10.1016/j.gene.2017.10.018.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (497) PDF downloads(47) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return